Engineered immune cells target tough blood cancers in new trial
NCT ID NCT03642626
First seen Jan 29, 2026 · Last updated Jun 08, 2026 · Updated 18 times
Summary
This study tests FDA-approved CAR-T cell therapy in 150 children and adults with certain blood cancers that have come back or not responded to treatment. Participants receive their own immune cells that have been reprogrammed to attack cancer cells. The goal is to see how many patients achieve remission and to monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.